EICHORCondition: Glioma · Sponsor: Leiden University Medical Center
Interested? Contact the study team ↓
A glioma is a primary brain tumor in adults that is characterized by a highly variable, but overall poor survival. The optimal timing of treatment is in part determined by the expected biological behavior of the tumor. At present the expected biological behavior, determined by the tumor genotype, can only be determined by tissue analysis, which requires brain surgery. Non-invasive and improved diagnostic methods are sought to obtain insight into the molecular profile of the tumor and the expected biological behavior to avoid surgery performed solely for diagnostic purposes. Vascularization is an important aspect of the biological behavior of a primary brain tumor. Tumor vascularization characteristics can be assessed by Magnetic Resonance Imaging (MRI), but with the currently available technology this can only be achieved with unacceptably long scan times. In this proposal, the investigators will develop and optimize a novel MRI protocol to gather a large set of quantitative vascularization parameters within an acceptable scan time. The hypothesis is that from such a 'vascular signature' the tumor genotype can be inferred by means of machine learning.
This description comes directly from the study's public registry record.
Daniëlle van Dorth, MSc · +31657056608 · D.van_Dorth@lumc.nl
Matthias JP van Osch, Prof Dr Ir · M.J.P.van_Osch@lumc.nl
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Patients scheduled for brain MRI with contrast injection as part of the clinical diagnostic procedure (cohort 1) * Patients diagnosed with suspected glioma scheduled for brain MRI as part of the clinical diagnostic procedure (cohort 2) * Patients with (suspected) glioma referred for tumor biopsy or resection (cohort 3) * Age ≥ 18 years (all cohorts) * Signed informed consent (all cohorts) Exclusion Criteria: * Subjects with contra-indications for an MRI exam * Subjects with reduced kidney function because of the risk on developing nephrogenic systemic fibrosis (NSF) under gadolinium-based contrast injection * Subjects with pregnancy * Subjects undergoing a clinical protocol that requires scanning during CA injection (cohort 1)
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Leiden University Medical Center | Leiden, Netherlands | Not Yet Recruiting |
| Erasmus University Medical Center | Rotterdam, Netherlands | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05274919